Literature DB >> 23090079

Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.

Ahmad A Tarhini1, Lisa H Butterfield, Yongli Shuai, William E Gooding, Pawel Kalinski, John M Kirkwood.   

Abstract

Changes in the biomarkers of host suppressor immune response were evaluated in patients with melanoma enrolled in 2 trials. Two similar cohorts of patients participating in the 2 studies were evaluated. The first (IFN/treme) tested interferon (IFN)-α2b and tremelimumab in metastatic melanoma and reported a response rate of 24%, 6.4 months median progression-free survival, and 21 months median overall survival. The second [toll-like receptor 9 (TLR)/GM] tested vaccination with MART-1, gp100, tyrosinase given with TLR-9 agonist and granulocyte-macrophage colony-stimulating factor and reported 9% response rate, median progression-free survival of 1.9 months, and median overall survival of 13.4 months. We monitored circulating T regulatory cells (T-reg) and myeloid-derived suppressor cells (MDSC) utilizing multicolor flow cytometry. In "IFN/treme," changes in circulating T-reg and MDSC were compared between baseline, day 29 (end of IFN-α induction) and day 85 (1 course). The CD4(+)CD25hi(+)CD39(+) T-reg percentage was increased most at day 85 (P = 0.018) and less significantly at day 29 (P = 0.09). There was a decrease in the percentage of MDSC populations taken in aggregate, which was most significant for monocytic MDSC (HLA-DR(+) low/CD14(+)) at day 29 (P < 0.0001) and day 85 (P = 0.001). In "TLR-9/GM," changes in T-reg and MDSC were compared between baseline and day 50 (4 vaccinations) and day 90 (8 vaccinations). There were no significant changes in T-reg or MDSC, except for a trend towards decreased (HLA-DR(+) low/CD14(+)) MDSC at day 50 (P = 0.07). Therefore, IFN/treme significantly downregulated MDSC suggesting a role on the significant clinical activity observed in this trial. T-reg findings suggest that IFN/treme induced clinically significant antitumor responses by inhibiting CTLA4 suppressive effects on T effectors, and less so by affecting T-reg.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090079      PMCID: PMC3513773          DOI: 10.1097/CJI.0b013e318272569b

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  54 in total

1.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Authors:  Ahmad A Tarhini; John Cherian; Stergios J Moschos; Hussein A Tawbi; Yongli Shuai; William E Gooding; Cindy Sander; John M Kirkwood
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

2.  Vitiligo in patients with metastatic melanoma: a good prognostic sign.

Authors:  J J Nordlund; J M Kirkwood; B M Forget; G Milton; D M Albert; A B Lerner
Journal:  J Am Acad Dermatol       Date:  1983-11       Impact factor: 11.527

Review 3.  Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.

Authors:  Paola Filipazzi; Veronica Huber; Licia Rivoltini
Journal:  Cancer Immunol Immunother       Date:  2011-11-27       Impact factor: 6.968

4.  Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer.

Authors:  M R Young; M A Wright; Y Lozano; J P Matthews; J Benefield; M M Prechel
Journal:  Int J Cancer       Date:  1996-07-29       Impact factor: 7.396

5.  Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Authors:  Ahmad A Tarhini; Siyang Leng; Stergios J Moschos; Yan Yin; Cindy Sander; Yan Lin; William E Gooding; John M Kirkwood
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

Review 6.  Derangement of immune responses by myeloid suppressor cells.

Authors:  Paolo Serafini; Carmela De Santo; Ilaria Marigo; Sara Cingarlini; Luigi Dolcetti; Giovanna Gallina; Paola Zanovello; Vincenzo Bronte
Journal:  Cancer Immunol Immunother       Date:  2003-10-30       Impact factor: 6.968

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

9.  Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo.

Authors:  J Rhodes; D H Jones; N M Bleehen
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

View more
  34 in total

1.  PD-1 Blockade Expands Intratumoral Memory T Cells.

Authors:  Antoni Ribas; Daniel Sanghoon Shin; Jesse Zaretsky; Juliet Frederiksen; Andrew Cornish; Earl Avramis; Elizabeth Seja; Christine Kivork; Janet Siebert; Paula Kaplan-Lefko; Xiaoyan Wang; Bartosz Chmielowski; John A Glaspy; Paul C Tumeh; Thinle Chodon; Dana Pe'er; Begoña Comin-Anduix
Journal:  Cancer Immunol Res       Date:  2016-01-19       Impact factor: 11.151

2.  Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Authors:  Cristina Maccalli; Diana Giannarelli; Filippo Capocefalo; Lorenzo Pilla; Ester Fonsatti; Anna Maria Di Giacomo; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

3.  Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Authors:  Lisa H Butterfield; Fengmin Zhao; Sandra Lee; Ahmad A Tarhini; Kim A Margolin; Richard L White; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; John M Kirkwood; David H Lawson
Journal:  Clin Cancer Res       Date:  2017-05-23       Impact factor: 12.531

Review 4.  Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Authors:  Michelle N Messmer; Colleen S Netherby; Debarati Banik; Scott I Abrams
Journal:  Cancer Immunol Immunother       Date:  2014-11-29       Impact factor: 6.968

Review 5.  Immune checkpoint blockade and interferon-α in melanoma.

Authors:  Imran Rafique; John M Kirkwood; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-02-14       Impact factor: 4.929

6.  Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

Authors:  Geoffrey T Gibney; Ragini R Kudchadkar; Ronald C DeConti; Melissa S Thebeau; Maria P Czupryn; Leticia Tetteh; Cabell Eysmans; Allison Richards; Michael J Schell; Kate J Fisher; Christine E Horak; H David Inzunza; Bin Yu; Alberto J Martinez; Ibrahim Younos; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2014-12-18       Impact factor: 12.531

7.  Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.

Authors:  Kimberly R Jordan; Rodabe N Amaria; Oscar Ramirez; Eryn B Callihan; Dexiang Gao; Michelle Borakove; Elizabeth Manthey; Virginia F Borges; Martin D McCarter
Journal:  Cancer Immunol Immunother       Date:  2013-09-27       Impact factor: 6.968

8.  Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

Authors:  Rikke B Holmgaard; Alexandra Brachfeld; Billel Gasmi; David R Jones; Marissa Mattar; Thompson Doman; Mary Murphy; David Schaer; Jedd D Wolchok; Taha Merghoub
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

Review 9.  Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

Authors:  Theofanis Floros; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 10.  Immune regulation and anti-cancer activity by lipid inflammatory mediators.

Authors:  Saraswoti Khadge; John Graham Sharp; Timothy R McGuire; Geoffrey M Thiele; Paul Black; Concetta DiRusso; Leah Cook; Lynell W Klassen; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2018-11-14       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.